TSH Biopharm Corporation Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,337	1,116	810.92	741.07	413.48
Revenue Growth (YoY)	19.79%	37.59%	9.43%	79.22%	-7.68%
Cost of Revenue	655.79	532.95	411.02	351.2	166.13
Gross Profit	680.74	582.76	399.9	389.87	247.36
Selling, General & Admin	436.86	384.16	313.39	289.71	168.33
Research & Development	24.62	27.99	24.81	31.09	23.52
Operating Expenses	462.37	412.91	336.27	323.85	191.74
Operating Income	218.37	169.86	63.63	66.03	55.62
Interest Expense	-0.8	-0.46	-0.69	-0.7	-0.08
Interest & Investment Income	14.83	11.98	13.06	9.71	8.46
Currency Exchange Gain (Loss)	-0.06	0.33	-0.43	6.39	-1.26
Other Non Operating Income (Expenses)	1.33	1.39	0.56	-0.13	-1.23
EBT Excluding Unusual Items	233.67	183.1	76.13	81.3	61.51
Gain (Loss) on Sale of Investments	1.11	-	-	-	-
Gain (Loss) on Sale of Assets	-	-0.87	-0.04	-0.06	-0
Asset Writedown	-	-8.8	-	-	-
Other Unusual Items	-	-	-	-	0.05
Pretax Income	234.79	173.43	76.09	81.24	61.55
Income Tax Expense	46.97	39.29	11.11	15.1	14.44
Earnings From Continuing Operations	187.82	134.15	64.98	66.14	47.11
Minority Interest in Earnings	-48.56	-21.06	-2.99	-4.25	-
Net Income	139.26	113.09	61.99	61.89	47.11
Net Income to Common	139.26	113.09	61.99	61.89	47.11
Net Income Growth	23.14%	82.44%	0.16%	31.38%	-23.49%
Shares Outstanding (Basic)	38	38	38	38	38
Shares Outstanding (Diluted)	38	38	38	38	38
Shares Change (YoY)	0.05%	0.04%	-0.05%	0.05%	0.01%
EPS (Basic)	3.63	2.95	1.61	1.61	1.23
EPS (Diluted)	3.62	2.94	1.61	1.61	1.23
EPS Growth	23.13%	82.61%	-	31.23%	-23.32%
Free Cash Flow	135	182.04	28.49	30.62	68.33
Free Cash Flow Per Share	3.51	4.74	0.74	0.80	1.78
Dividend Per Share	2.610	2.120	1.280	1.600	1.500
Dividend Growth	23.11%	65.63%	-20.00%	6.67%	-16.67%
Gross Margin	50.93%	52.23%	49.31%	52.61%	59.82%
Operating Margin	16.34%	15.22%	7.85%	8.91%	13.45%
Profit Margin	10.42%	10.14%	7.64%	8.35%	11.39%
Free Cash Flow Margin	10.10%	16.32%	3.51%	4.13%	16.52%
EBITDA	231.38	185.11	77.65	79.28	60.87
EBITDA Margin	17.31%	16.59%	9.58%	10.70%	14.72%
D&A For EBITDA	13.01	15.26	14.02	13.25	5.26
EBIT	218.37	169.86	63.63	66.03	55.62
EBIT Margin	16.34%	15.22%	7.85%	8.91%	13.45%
Effective Tax Rate	20.00%	22.65%	14.61%	18.58%	23.46%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.